Модуляция возбудимости коры головного мозга у крысы с помощью повторяющейся транскраниальной магнитной стимуляции

Executive Industry Relevance

Modulating cortical excitability via rTMS in rodent models supports target validation in neuroscience drug discovery by enabling mechanistic interrogation of neuronal pathways. This approach enhances predictive confidence in early-stage programs by linking stimulation parameters to quantifiable neurophysiological outputs such as calcium influx and synaptic plasticity. It informs go/no-go decisions for CNS-targeted therapeutics by providing a reproducible system to assess target engagement and functional modulation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of cortical excitability mechanisms to validate therapeutic hypotheses in neurological disease models.
• Operational Value: Provides a standardized method to assess target modulation through motor threshold determination and contralateral forepaw response.

Screening & Assay Development

• Scientific Value: Generates quantitative dependent variable measurements such as muscle contraction frequency and calcium influx to support assay standardization.
• Operational Value: Facilitates reproducible stimulation protocols at defined intensities (100-110% MT) and frequencies (1 Hz or 20 Hz) for consistent readouts.

Translational & Preclinical Research

• Scientific Value: Supports disease-relevant system modeling by linking rTMS-induced neurotrophic factor production to synaptic plasticity and excitatory neurotransmitter receptor upregulation.
• Operational Value: Enables continuity from discovery through preclinical validation by allowing recovery-period assessment of rTMS-induced changes in cortical excitability.

Pipeline & Workflow Integration

This method integrates into the discovery continuum from target validation through preclinical research by providing a platform for mechanistic de-risking of CNS targets via non-invasive neuromodulation.

• Discovery Biology: Supports hypothesis testing and pathway clarification through controlled induction of electrical activity in cortical neurons.
• Screening: Delivers assay readiness and reproducibility via standardized motor threshold establishment and unilateral stimulation verification.
• Analytics: Enables quantitative measurement of dependent variables such as contralateral forepaw contractions and calcium channel activation to compare stimulation conditions.
• Translational Research: Connects to preclinical continuity through assessment of neurotrophic factor production and synaptic plasticity as biomarkers of target engagement.
• Enterprise Reuse: Establishes a reusable capability for evaluating CNS-targeted compounds across multiple frequencies and intensities in rodent models.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence through mechanistic de-risking of cortical excitability mechanisms and target validation in neurological models.
• Operational Value: Standardization and reproducibility via motor threshold determination and temperature-controlled stimulation delivery.
• Strategic Value: Improved go/no-go decisions by linking rTMS parameters to neurophysiological outputs that inform target modulation efficacy.
• Portfolio Impact: Risk-adjusted prioritization of CNS programs based on reproducible assessment of target engagement and functional plasticity changes.

Implementation Considerations

• Required expertise in neurophysiology and rodent stereotaxic procedures for accurate coil placement over primary motor cortex.
• Instrumentation needs include figure-of-eight magnetic coil, water cooling system, and stimulation software console for intensity and frequency control.
• Cross-team standardization requires unified protocols for motor threshold verification (five or more contralateral forepaw contractions) and unilateral stimulation confirmation.
• Adaptation considerations across model systems involve adjusting stimulation intensity relative to motor threshold and verifying absence of ipsilateral contraction.
• Practical limitations include maintaining anesthesia depth and body temperature (37°C) to ensure consistent neuronal responsiveness during stimulation.

Biopharma FAQs